← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Asclepix Therapeutics, Inc.
Baltimore, MD
$3,518,519
Total funding
6
Grants
Funding over time
peak $1.2M · FY2014–19$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,518,519 · 6
By mechanism
R44$2,096,994 · 1
R43$1,163,516 · 4
U43$258,009 · 1
Investigators at Asclepix Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IND-enabling development of a biomimetic peptide drug for macular edema$1,165,695
R44 · FY2017 · EY
IND-enabling development of a biomimetic peptide drug for macular edema$824,075
R44 · FY2018 · EY
Therapeutic peptide for hepatocellular carcinoma$299,983
R43 · FY2018 · CA
Immunoactivating Peptide AXT201 in Combination with Anti-PD-1 Antibody for Triple-Negative Breast Cancer$299,815
R43 · FY2019 · CA
Development of a mimetic multimodal peptide for the treatment of macular edema$278,133
R43 · FY2015 · EY
Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors$258,009
U43 · FY2014 · CA
Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$189,603
R43 · FY2014 · EY
IND-enabling development of a biomimetic peptide drug for macular edema$107,224
R44 · FY2018 · EY
Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$70,982
R43 · FY2015 · EY
Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$25,000
R43 · FY2014 · EY